On the stock market since 2017, it operates in the world of health and science. It has 52 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
If every debt were paid off today, $14.0M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $14.0M in the vault; even if every debt were paid off, $14.0M would remain.
Over the last 12 months, company executives reported 26 buys and 16 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $5.50 — 615% above today’s price.
The stock sits at $0.77. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 4/10.
On our five-subject report card, LPTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LPTX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.